GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
October 24, 2024 08:30 ET
|
GRI Bio, Inc.
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of...
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia
September 26, 2024 08:00 ET
|
GRI Bio, Inc.
MHRA and HREC authorization in Australia further expands and will potentially accelerate enrollment in ongoing U.S. and UK Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment...
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 08:00 ET
|
GRI Bio, Inc.
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 ...
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
March 04, 2024 08:30 ET
|
GRI Bio, Inc.
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and...
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
December 05, 2023 09:05 ET
|
GRI Bio, Inc.
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant...
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 15, 2023 08:05 ET
|
GRI Bio, Inc.
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are...
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 08:05 ET
|
GRI Bio, Inc.
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment...